The Wee1 inhibitor MK1775 (AZD1775) is currently being tested in clinical trials for cancer treatment. Here, we show that the p53 target and CDK inhibitor p21 protects against MK1775-induced DNA damage during S-phase. Cancer and normal cells deficient for p21 (HCT116 p21-/-, RPE p21-/-, and U2OS transfected with p21 siRNA) showed higher induction of the DNA damage marker γH2AX in S-phase in response to MK1775 compared to the respective parental cells. Furthermore, upon MK1775 treatment the levels of phospho-DNA PKcs S2056 and phospho-RPA S4/S8 were higher in the p21 deficient cells, consistent with increased DNA breakage. Cell cycle analysis revealed that these effects were due to an S-phase function of p21, but MK1775-induced S-phase CDK activity was not altered as measured by CDK-dependent phosphorylations. In the p21 deficient cancer cells MK1775-induced cell death was also increased. Moreover, p21 deficiency sensitized to combined treatment of MK1775 and the CHK1-inhibitor AZD6772, and to the combination of MK1775 with ionizing radiation. These results show that p21 protects cancer cells against Wee1 inhibition and suggest that S-phase functions of p21 contribute to mediate such protection. As p21 can be epigenetically downregulated in human cancer, we propose that p21 levels may be considered during future applications of Wee1 inhibitors.

b Department of Cancer Cell Biology Institute of Molecular Genetics of the ASCR Prague Czech Republic

Department of Radiation Biology Institute for Cancer Research Norwegian Radium Hospital Oslo University Hospital Oslo Norway

See more in PubMed

McGowan CH, Russell P.. Cell cycle regulation of human WEE1. Embo J. 1995. May 15;14(10):2166–2175. PubMed PMID: 7774574; PubMed Central PMCID: PMCPMC398322. PubMed PMC

Parker LL, Piwnica-Worms H.. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science. 1992. September 25;257(5078):1955–1957. PubMed PMID: 1384126. PubMed

Hirai H, Iwasawa Y, Okada M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009. November;8(11):2992–3000. PubMed PMID: 19887545. PubMed

Mueller S, Haas-Kogan DA. WEE1 Kinase as a target for cancer therapy. J Clin Oncol. 2015. October 20;33(30):3485–3487. PubMed PMID: 26215953. . PubMed

Watanabe N, Broome M, Hunter T. Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. Embo J. 1995. May 1;14(9):1878–1891. PubMed PMID: 7743995; PubMed Central PMCID: PMCPMC398287. PubMed PMC

Anda S, Rothe C, Boye E, et al. Consequences of abnormal CDK activity in S phase. Cell Cycle. 2016;15(7):963–973. PubMed PMID: 26918805; PubMed Central PMCID: PMCPMC4889304. . PubMed PMC

Beck H, Nähse V, Larsen MS, et al. Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase. J Cell Biol. 2010. March 8;188(5):629–638. PubMed PMID: 20194642; PubMed Central PMCID: PMCPMC2835936. PubMed PMC

Beck H, Nähse-Kumpf V, Larsen MS, et al. Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol Cell Biol. 2012. October;32(20):4226–4236. PubMed PMID: 22907750; PubMed Central PMCID: PMCPMC3457333. PubMed PMC

Toledo LI, Altmeyer M, Rask MB, et al. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell. 2013. November 21;155(5):1088–1103. PubMed PMID: 24267891. PubMed

Guertin AD, Li J, Liu Y, et al. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Mol Cancer Ther. 2013. August;12(8):1442–1452. PubMed PMID: 23699655. PubMed

Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst). 2016. June;42:63–71. PubMed PMID: 27156098. PubMed

Ivanovska I, Ball AS, Diaz RL, et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol. 2008. April;28(7):2167–2174. PubMed PMID: 18212054; PubMed Central PMCID: PMCPMC2268421. PubMed PMC

He Y, Yu B. MicroRNA-93 promotes cell proliferation by directly targeting P21 in osteosarcoma cells. Exp Ther Med. 2017. May;13(5):2003–2011. PubMed PMID: 28565800; PubMed Central PMCID: PMCPMC5443279. . PubMed PMC

Bi YY, Shen G, Quan Y, et al. Long noncoding RNA FAM83H-AS1 exerts an oncogenic role in glioma through epigenetically silencing CDKN1A (p21). J Cell Physiol. 2018. June 5 PubMed PMID: 29870057 DOI:10.1002/jcp.26813. PubMed DOI

Ni N, Song H, Wang X, et al. Up-regulation of long noncoding RNA FALEC predicts poor prognosis and promotes melanoma cell proliferation through epigenetically silencing p21. Biomed Pharmacother. 2017. December;96:1371–1379. PubMed PMID: 29196104. PubMed

Chen Z, Chen X, Chen P, et al. Long non-coding RNA SNHG20 promotes non-small cell lung cancer cell proliferation and migration by epigenetically silencing of P21 expression. Cell Death Dis. 2017. October 5;8(10):e3092 PubMed PMID: 28981099; PubMed Central PMCID: PMCPMC5682652. PubMed PMC

Brugarolas J, Chandrasekaran C, Gordon JI, et al. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 1995. October 12;377(6549):552–557. PubMed PMID: 7566157. PubMed

Chen J, Saha P, Kornbluth S, et al. Cyclin-binding motifs are essential for the function of p21CIP1. Mol Cell Biol. 1996. September;16(9):4673–4682. PubMed PMID: 8756624; PubMed Central PMCID: PMCPMC231467. PubMed PMC

Deng C, Zhang P, Harper JW, et al. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 1995. August 25;82(4):675–684. PubMed PMID: 7664346. PubMed

Bunz F, Dutriaux A, Lengauer C, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998. November 20;282(5393):1497–1501. PubMed PMID: 9822382. PubMed

Waga S, Hannon GJ, Beach D, et al. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 1994. June 16;369(6481):574–578. PubMed PMID: 7911228. PubMed

Moldovan GL, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. Cell. 2007. May 18;129(4):665–679. PubMed PMID: 17512402. . PubMed

Soria G, Speroni J, Podhajcer OL, et al. p21 differentially regulates DNA replication and DNA-repair-associated processes after UV irradiation. J Cell Sci. 2008. October 1;121(Pt 19):3271–3282. PubMed PMID: 18782865. PubMed

Mansilla SF, Bertolin AP, Bergoglio V, et al. Cyclin Kinase-independent role of p21(CDKN1A) in the promotion of nascent DNA elongation in unstressed cells. Elife. 2016. October 14;5 PubMed PMID: 27740454; PubMed Central PMCID: PMCPMC5120883 DOI:10.7554/eLife.18020. PubMed DOI PMC

Maya-Mendoza A, Moudry P, Merchut-Maya JM, et al. High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018. July;559(7713):279–284. PubMed PMID: 29950726 DOI: 10.1038/s41586-018-0261-5. PubMed DOI

Liu Y, Kwiatkowski DJ. Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target. Mol Cancer Ther. 2015. January;14(1):174–182. PubMed PMID: 25349305; PubMed Central PMCID: PMCPMC4297264. . PubMed PMC

Origanti S, Cai SR, Munir AZ, et al. Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells. Oncogene. 2013. January 31;32(5):577–588. PubMed PMID: 22430210; PubMed Central PMCID: PMCPMC3381958. PubMed PMC

Petermann E, Woodcock M, Helleday T. Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci U S A. 2010. September 14;107(37):16090–16095. PubMed PMID: 20805465; PubMed Central PMCID: PMCPMC2941317. . PubMed PMC

Syljuåsen RG, Sørensen CS, Hansen LT, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol. 2005. May;25(9):3553–3562. PubMed PMID: 15831461; PubMed Central PMCID: PMCPMC1084285. PubMed PMC

Sørensen CS, Syljuåsen RG. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res. 2012. January;40(2):477–486. PubMed PMID: 21937510; PubMed Central PMCID: PMCPMC3258124. . PubMed PMC

Hasvold G, Lund-Andersen C, Lando M, et al. Hypoxia-induced alterations of G2 checkpoint regulators. Mol Oncol. 2016. May;10(5):764–773. PubMed PMID: 26791779; PubMed Central PMCID: PMCPMC5423158. PubMed PMC

Hauge S, Naucke C, Hasvold G, et al. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading. Oncotarget. 2017. February 14;8(7):10966–10979. PubMed PMID: 28030798; PubMed Central PMCID: PMCPMC5355238. PubMed PMC

Tkacz-Stachowska K, Lund-Andersen C, Velissarou A, et al. The amount of DNA damage needed to activate the radiation-induced G2 checkpoint varies between single cells. Radiother Oncol. 2011. October;101(1):24–27. PubMed PMID: 21722983. PubMed

Ashley AK, Shrivastav M, Nie J, et al. DNA-PK phosphorylation of RPA32 Ser4/Ser8 regulates replication stress checkpoint activation, fork restart, homologous recombination and mitotic catastrophe. DNA Repair (Amst). 2014. September;21:131–139. PubMed PMID: 24819595; PubMed Central PMCID: PMCPMC4135522. PubMed PMC

Chen BP, Chan DW, Kobayashi J, et al. Cell cycle dependence of DNA-dependent protein kinase phosphorylation in response to DNA double strand breaks. J Biol Chem. 2005. April 15;280(15):14709–14715. PubMed PMID: 15677476. PubMed

Pfister SX, Markkanen E, Jiang Y, et al. Inhibiting Wee1 selectively kills histone h3k36me3-deficient cancers by dNTP starvation. Cancer Cell. 2015. November 9;28(5):557–568. PubMed PMID: 26602815; PubMed Central PMCID: PMCPMC4643307. PubMed PMC

Mak JP, Man WY, Ma HT, et al. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis. Oncotarget. 2014. November 15;5(21):10546–10557. PubMed PMID: 25301733; PubMed Central PMCID: PMCPMC4279392. PubMed PMC

Rego MA, Harney JA, Mauro M, et al. Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor. Oncogene. 2012. January 19;31(3):366–375. PubMed PMID: 21685936; PubMed Central PMCID: PMCPMC3974337. PubMed PMC

Yang Y, Gao Y, Mutter-Rottmayer L, et al. DNA repair factor RAD18 and DNA polymerase Polkappa confer tolerance of oncogenic DNA replication stress. J Cell Biol. 2017. October 2;216(10):3097–3115. PubMed PMID: 28835467; PubMed Central PMCID: PMCPMC5626543. PubMed PMC

Bridges KA, Hirai H, Buser CA, et al. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res. 2011. September 1;17(17):5638–5648. PubMed PMID: 21799033; PubMed Central PMCID: PMCPMC3167033. PubMed PMC

Leijen S, Beijnen JH, Schellens JH. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol. 2010. August;5(3):186–191. PubMed PMID: 20406171. PubMed

Leijen S, van Geel RM, Pavlick AC, et al. Phase I study evaluating WEE1 Inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol. 2016. December 20;34(36):4371–4380. PubMed PMID: 27601554. PubMed PMC

Leijen S, van Geel RM, Sonke GS, et al. Phase II study of WEE1 Inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J Clin Oncol. 2016. December 20;34(36):4354–4361. PubMed PMID: 27998224. PubMed

Rajeshkumar NV, De Oliveira E, Ottenhof N, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res. 2011. May 1;17(9):2799–2806. PubMed PMID: 21389100; PubMed Central PMCID: PMCPMC3307341. PubMed PMC